Reference number : 236-2017-2018-Q4-00663, amendment number : , agreement type : G, recipient legal name : Weaver, Donald F, recipient country : CA, recipient province : ON, recipient city : Toronto, recipient postal code : M5G 2C4, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 765000.0, agreement start date : 2018-04-01, agreement end date : 2022-03-31, description english : Design and Development of Brain Permeant Indoleamine-2,3-Dioxygenase Inhibitors, description french : Design and Development of Brain Permeant Indoleamine-2,3-Dioxygenase Inhibitors, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2018-19 to 2021-22), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2018-19 à 2021-22), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada